Freenome, Inc. (Nasdaq: FRNM) SEC filings document the company’s public-company disclosures as an early cancer detection business developing blood-based screening tests. The most relevant filings cover registration activity, business-combination history, material events, capital structure, governance matters, clinical and regulatory disclosures, operating results, and financial results.
Freenome entered the public market through a business combination with Perceptive Capital Solutions Corp., a blank-check company, after which the combined company took the Freenome, Inc. name. Its registration statements and material-event reports carry the detail behind that transition, the resulting share structure, and the securities registered for resale by selling securityholders.
For Freenome, clinical and regulatory filing language is especially important because the company’s disclosed business depends on blood-based cancer screening tests, FDA status, and commercialization arrangements. Investors may review filings for discussion of SimpleScreen™ CRC, SimpleScreen™ Lung, FDA-related disclosures, technology descriptions, risk factors, material agreements, and financial reporting.
Quarterly reports, annual reports, registration statements, proxy materials, Form 4 insider-transaction filings, and Form 8-K material-event reports can each answer different questions when they are filed. For Freenome, these documents may show how the company describes its multiomics platform, Abbott commercialization agreement, governance structure, capital structure, operating results, and clinical or regulatory matters.
Freenome, Inc. (FRNM) is the issuer whose common stock is the subject of an amended ownership report by Aberdeen Group plc and abrdn Inc., each reporting beneficial ownership of 656,676 shares, or 0.61% of the class. Each reports shared voting and dispositive power over 656,676 shares and zero sole voting or dispositive power. The ownership structure identifies Aberdeen Group plc as the parent, abrdn Holdings Limited as the intermediate holding company, and abrdn Inc. as beneficially owning shares on behalf of underlying clients.
Freenome, Inc. has registered 75,188,742 shares of common stock for resale by selling securityholders. Separately, Freenome announced the launch of SimpleScreen Lung and a combined screening option pairing it with SimpleScreen CRC through one blood draw, using two independently validated, indication-specific tests.
SimpleScreen Lung is a laboratory-developed test intended for adults ages 50 to 80 with a ≥20 pack-year smoking history who are not currently participating in guideline-recommended screening; it has not been reviewed or cleared/approved by the FDA. In an independent cohort of 172 lung cancer cases and 436 controls, it showed 85% sensitivity at 50% specificity and 99.8% negative predictive value. The FDA-approved SimpleScreen CRC test showed 81% sensitivity for CRC, 90% specificity for advanced colorectal neoplasia and 99.9% negative predictive value in PREEMPT CRC, which enrolled more than 48,000 participants.
Freenome, Inc. announced the launch of SimpleScreen™ Lung and an option to pair it with FDA-approved SimpleScreen™ CRC in a single blood draw, using two independently validated, indication-specific tests. SimpleScreen Lung is intended for adults ages 50 to 80 with a ≥20 pack-year smoking history who are not currently participating in guideline-recommended screening; it is a laboratory-developed test that has not been reviewed or cleared/approved by the FDA.
In an independent cohort of 172 lung cancer cases and 436 controls, SimpleScreen Lung achieved 85% sensitivity at 50% specificity and a 99.8% negative predictive value. Sensitivity was 82%, 75%, 91% and 94% for stages I through IV, respectively. SimpleScreen CRC demonstrated 81% sensitivity for colorectal cancer, 90% specificity for advanced colorectal neoplasia and a 99.9% negative predictive value in an analysis from PREEMPT CRC, which enrolled more than 48,000 participants.
Freenome, Inc. (FRNM) reported that Chief Executive Officer and director Elliott Aaron Matthew had 71,920 shares of common stock withheld on September 2, 2026, at $15.25 per share to satisfy tax withholding obligations arising from the vesting of restricted stock units. After this tax-withholding disposition, he holds 345,976 shares of Freenome common stock directly. No Rule 10b5-1 trading plan is reported for this transaction.
Freenome, Inc. (FRNM) has a significant shareholder group led by Roche entities that jointly report beneficial ownership of a large minority stake in the company. Roche Holdings, Inc., Roche Finance Ltd, and Roche Holding Ltd (the “Reporting Persons”) have filed a Schedule 13G disclosing their ownership in Freenome’s common stock.
The Reporting Persons report beneficial ownership of 18,692,766 shares of Freenome common stock, representing 17.4% of the class, based on 107,446,814 shares outstanding as of July 20, 2026. Of these, 18,055,686 shares are held of record by Roche Holdings, Inc. and 637,080 shares are held of record by Roche Finance Ltd. The Reporting Persons state they have 0 shares with sole voting or dispositive power and 18,692,766 shares with shared voting and dispositive power.
Freenome, Inc. (FRNM) filed a resale shelf prospectus on Form S-1/424B3 covering up to 75,188,742 shares of common stock that may be offered from time to time by selling securityholders. The shares comprise PIPE shares, business-combination consideration shares, option and RSU shares, Roche note conversion shares and Private Warrant shares.
Freenome will not receive proceeds from sales by selling securityholders, but may receive up to approximately $36.3 million if options and the Private Warrant are exercised for cash, for general corporate purposes. The company focuses on blood-based multiomics cancer screening, with FDA-approved SimpleScreen CRC, and operates as an emerging growth and smaller reporting company with significant historical losses and substantial R&D, regulatory, competitive, financing, data-privacy, cybersecurity and AI-related risks described in detail in its risk factors.
Freenome, Inc. (FRNM) has filed an S-1 to register up to 75,188,742 shares of common stock for resale by existing holders, including PIPE investors, the SPAC sponsor and initial shareholders, former Freenome Holdings equity holders, option and RSU holders, Roche (via a convertible note conversion) and a private warrant holder. Freenome will not receive proceeds from these secondary sales.
The company may receive up to $36.3 million if all registered options and the private warrant are exercised for cash; shares outstanding were 107,446,814 at the Business Combination closing and would be 112,549,251 assuming full exercise. Freenome is an early cancer detection company focused on blood-based, multiomics tests powered by AI/ML, initially centered on colorectal cancer (CRC). Its SimpleScreen CRC blood test has FDA approval for average‑risk adults 45+, is supported by the PREEMPT CRC study, and will be commercialized in the U.S. by Abbott under an exclusive agreement.
Freenome reports large, ongoing losses as it scales: net losses of $132.6 million for the six months ended June 30 2026, and $219.3 million and $274.4 million for 2025 and 2024, with an accumulated deficit of $1.5 billion. Management believes existing cash, including Business Combination and PIPE proceeds, will fund operations into 2028 but highlights potential future capital needs. The company is an emerging growth company and smaller reporting company, allowing reduced disclosure and delayed adoption of new accounting standards.
Freenome, Inc. received an updated Schedule 13G/A (Amendment No. 2) from ADAR1 Capital Management, LLC, ADAR1 Capital Management GP, LLC, and Daniel Schneeberger regarding Class A Ordinary Shares. The reporting group collectively reports beneficial ownership of 674,695 Class A Ordinary Shares, representing 8.3% of the class, based on 8,157,242 shares outstanding as of June 30, 2026. These shares are held through ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC and other separately managed accounts, with the reporting persons having shared voting and dispositive power and no sole voting or dispositive power.
Highbridge Capital Management, LLC, an investment adviser to certain funds, reports that it currently has no beneficial ownership of Freenome, Inc. common stock, with 0 shares and 0.0% of the class, and no sole or shared voting or dispositive power.
The filing notes that, as of June 30, 2026, Highbridge may have been deemed to beneficially own 661,493 Class A Ordinary Shares of Freenome, representing 8.1% of the Class A Ordinary Shares then outstanding, based on 8,157,242 Class A Ordinary Shares reported outstanding as of June 17, 2026. Highbridge emphasizes that the report should not be construed as an admission that it or related persons are beneficial owners for all purposes.